Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

fresenius kabi (schweiz) ag - adalimumabum - solution injectable en stylo prérempli - lösung: adalimumabum 40 mg, acidum citricum monohydricum, dinatrii phosphas dihydricus, natrii dihydrogenophosphas dihydricus, mannitolum, polysorbatum 80, natrii chloridum, trinatrii citras dihydricus, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - rheumatoide l'arthrite, polyartikuläre juvénile idiopathische l'arthrite, le psoriasis, l'arthrite, ankylosierende de spondylarthrite ankylosante, maladie de crohn, servir ulcérative, le psoriasis en plaques bei erwachsenen, hidrosadénite - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

medius ag - adalimumabum - solution injectable en stylo prérempli - adalimumabum 40 mg, natrii hydrogenoglutamas anhydricus, sorbitolum 38.2 mg, methioninum, polysorbatum 80, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml corresp. natrium 184 µg. - rheumatoide arthritis, polyartikuläre juvenile arthritis, psoriatische arthritis, ankylosierende arthritis, morbus crohn bei erwachsenen sowie kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, hidradenitis suppurativa - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

medius ag - adalimumabum - injektionslösung in einer durchstechflasche - adalimumabum 40 mg, natrii hydrogenoglutamas anhydricus, sorbitolum 38.2 mg, methioninum, polysorbatum 80, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml corresp. natrium 184 µg. - polyartikuläre juvenile arthritis, morbus crohn bei kindern und jugendlichen - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

medius ag - adalimumabum - solution injectable dans une seringue préremplie - adalimumabum 40 mg, natrii hydrogenoglutamas anhydricus, sorbitolum 38.2 mg, methioninum, polysorbatum 80, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml corresp. natrium 184 µg. - rheumatoide arthritis, polyartikuläre juvenile arthritis, psoriatische arthritis, ankylosierende arthritis, morbus crohn bei erwachsenen sowie kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, hidradenitis suppurativa - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - adalimumabum - solution injectable en stylo prérempli - adalimumabum 40 mg, histidinum, histidini hydrochloridum monohydricum, dinatrii edetas corresp. natrium 5 µg, saccharum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - rheumatoide arthritis, polyartikuläre juvenile arthritis, psoriasis-arthritis, ankylosierende spondylitis, morbus crohn bei erwachsenen, kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, uveitis - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - adalimumabum - solution injectable dans une seringue préremplie - adalimumabum 40 mg, histidinum, histidini hydrochloridum monohydricum, dinatrii edetas corresp. natrium 5 µg, saccharum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.8 ml. - rheumatoide arthritis, polyartikuläre juvenile arthritis, psoriasis-arthritis, ankylosierende spondylitis, morbus crohn bei erwachsenen, kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, uveitis - biotechnologika

Union européenne - français - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rejet de greffe - immunosuppresseurs - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - infliximabum - solution injectable en stylo prérempli - infliximabum 120 mg, acidum aceticum, natrii acetas trihydricus, sorbitolum 45 mg, polysorbatum 80, aqua ad iniectabile, q.s. ad solutionem pro 1 ml corresp. natrium 0.16 mg. - polyarthrite rhumatoïde, morbus crohn chez l'adulte, colite ulcéreuse chez l'adulte, spondylarthrite ankylosante - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - adalimumabum - solution injectable dans une seringue préremplie - adalimumabum 20 mg, saccharum, polysorbatum 80, acidum aceticum glaciale, natrii hydroxidum corresp. natrium 0.13 mg, aqua ad iniectabile q.s. ad solutionem pro 0.4 ml. - rheumatoide arthritis, polyartikuläre juvenile idiopathische arthritis, psoriasis-arthritis, ankylosierende spondylitis (morbus bechterew), morbus crohn bei erwachsenen sowie kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen, hidradenitis suppurativa, uveitis - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - adalimumabum - solution injectable en seringue pré-remplie - adalimumabum 20 mg, acidum adipicum, acidum citricum monohydricum, natrii chloridum, mannitolum, polysorbatum 80, natrii hydroxidum aut acidum hydrochloridum, aqua ad iniectabile ad solutionem pro 0.4 ml corresp. natrium 1.17 mg. - rheumatoide arthritis, polyartikuläre juvenile idiopathische arthritis, psoriasis-arthritis, ankylosierende spondylitis (morbus bechterew), morbus crohn bei erwachsenen sowie kindern und jugendlichen, colitis ulcerosa, psoriasis bei erwachsenen und jugendlichen ab 47 kg körpergewicht, hidradenitis suppurativa (acne inversa), uveitis - biotechnologika